Malignant hypertension (MH) is a severe form of arterial hypertension, which is characterized by a sharp increase in blood pressure, accompanied by progressive damage to target organs. This disease, as a rule, manifests itself by an increase in systolic and diastolic pressure above 180/120 mm Hg, which requires immediate medical attention. Unlike normal hypertension, the malignant form has a more rapid and life-threatening course, often ending in the final stage of renal failure, stroke, heart failure and other serious complications. MH is most often recorded in young people and can be considered a manifestation of another disease, for example, renal pathology.
History of the disease and interesting historical facts
Malignant hypertension was first described in 1928 by physician and preacher A. A. Turner, who observed patients with sudden onset of high blood pressure and signs of organ damage. In the following decades, researchers began to associate MH with various pathogenetic mechanisms, such as renal diseases, primarily glomerulonephritis, and systemic diseases, including systemic lupus erythematosus. In 1936, scientists characterized the clinical manifestations of malignant hypertension, pointing out characteristic changes in the fundus, such as exudation, optic disc edema, and retinal angiopathy. Since then, malignant hypertension has become an important subject of study in cardiology and nephrology, and modern approaches to the diagnosis and treatment of this condition have been developed.
Epidemiology
Malignant hypertension is relatively rare in the population, but its prevalence has significant geographical and ethnic differences. According to various epidemiological studies, the incidence ranges from 0.1% to 2% among all cases of arterial hypertension, with maximum rates in the 30-50 age group. In large cities and regions with a high degree of ecology, the incidence rate may increase due to stress factors and unhealthy lifestyle. According to the World Health Organization, malignant hypertension causes more than 2.5 million deaths annually, making it a key problem for public health in general.
Genetic predisposition to this disease
Research shows that genetic predisposition plays an important role in the pathogenesis of malignant hypertension. In particular, several genes involved in the development of this disease have been identified. These include:
- Genes responsible for regulating the renin-angiotensin system (RAS), such as AGT, ACE and AGTR1.
- Genes involved in salt metabolism, such as SLC12A3.
- Genes associated with inflammation, such as IL-6.
- Genes responsible for vascular function, including NOS3 and others.
Mutations in these genes can lead to impaired blood pressure regulation and increased sensitivity to high salt levels, which is a major trigger for malignant hypertension. The focus is on the polygenic effects and their interaction with environmental factors.
Risk factors for the development of this disease
Malignant hypertension can develop under the influence of various risk factors, both modifiable and non-modifiable. These include:
- Heredity: presence of cases of high arterial hypertension in the family.
- Age: Increased risk in younger age groups.
- Overweight and obesity: Being overweight puts additional stress on your cardiovascular system.
- Salt intake: Excess salt intake has been linked to high blood pressure.
- Smoking: has a negative effect on the vascular system and can cause vasoconstriction.
- Physical activity: Lack of physical activity contributes to the development of metabolic syndrome.
- Stress: Chronic stress increases the risk of developing cardiovascular disease.
- Other medical conditions: such as diabetes, chronic kidney disease, and autoimmune diseases.
All of these factors interact and can significantly increase the risk of developing malignant hypertension, so controlling them is a key aspect of prevention.
Diagnosis of this disease
Diagnosis of malignant hypertension requires a comprehensive approach and includes several stages:
- Main symptoms: sudden dizziness, severe headache, visual disturbances, shortness of breath, swelling.
- Laboratory tests: creatinine levels, electrolytes, renin and angiotensin levels.
- Radiological examinations: ultrasound of the kidneys, MRI or CT of organs that can reveal kidney pathology.
- Other types of diagnostics: electrochemical methods and X-ray studies to assess the state of the cardiovascular system.
- Differential diagnosis: It is important to exclude other causes of high blood pressure, such as endocrine disorders, renal diseases and vascular pathologies.
Developing correct and timely diagnostics is important for choosing adequate therapy and improving prognosis.
Treatment
Treatment of malignant hypertension combines both pharmacological and non-pharmacological approaches. It includes:
- General treatment: Incorporating healthy lifestyle recommendations into daily practice, such as weight control, smoking cessation and regular physical activity.
- Pharmacological treatment: use of antihypertensive drugs such as renin-angiotensin system blockers, diuretics, β-blockers and calcium channel blockers.
- Surgical treatment: In cases involving kidney disease, kidney surgery or nephrectomy may be required.
- Other treatments: Use of alternative methods and rehabilitation, including physical therapy and psychological support.
All stages of treatment require an individual approach and may vary depending on the patient’s condition and the degree of manifestation of the disease.
List of medications used to treat this disease
The main classes of drugs used in the treatment of malignant hypertension include:
- Angiotensin-converting enzyme (ACE) inhibitors: enalapril, ramipril;
- Angiotensin receptor antagonists: losartan, valsartan;
- Calcium antagonists: amlodipine, verapamil;
- Diuretics: hydrochlorothiazide, furosemide;
- β-blockers: metoprolol, carvedilol;
- Alpha agonists: clonidine.
It is important to take into account that the choice of drug should be based on the individual pathology and concomitant diseases of the patient.
Disease monitoring
Monitoring the condition of a patient with malignant hypertension includes the following steps:
- Blood pressure monitoring: regular monitoring and documentation of pressure levels to assess the dynamics of the condition.
- Prognosis: With early detection and adequate therapy, a significant improvement in prognosis is possible.
- Complications: Requires attention to potential complications such as uncontrolled hypertension and stroke.
Regular visits to the doctor and end-organ screening are essential to prevent serious consequences.
Age-related features of the disease
Malignant hypertension is most often found in people aged 30 to 50 years, but there are a number of age-related features:
- At a young age, patients usually have a more aggressive course of the disease and a greater predisposition to organ damage.
- In older people, malignant hypertension may be combined with other cardiovascular diseases, such as coronary heart disease and aortic stenosis.
- In childhood, malignant hypertension may be associated with primary renal pathology or inherited syndromes such as Wolff-Parkinson-White syndrome.
The overall disease management strategy should take into account the age characteristics and comorbidities of patients.
Questions and Answers
- What are the main symptoms of malignant hypertension?
Answer: The main symptoms include severe headaches, dizziness, shortness of breath, swelling and visual disturbances. - How to diagnose malignant hypertension?
Answer: Diagnostics includes blood pressure measurement, laboratory tests, radiological examinations and differential diagnosis with other diseases. - What is the treatment structure for this disease?
Answer: Treatment includes both general measures, pharmacological therapy and in some cases surgical intervention. - What is the importance of blood pressure control?
Answer: Regular blood pressure monitoring helps control the progression of the disease and prevent complications. - What are the age-related characteristics of malignant hypertension?
Answer: In younger patients, the disease is more aggressive, while in older patients it may be combined with other cardiovascular diseases.
